GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
BHP Shares Fall as Jansen Potash Project Costs Surge 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
CVS Health (NYSE: CVS) announced Friday that it has reduced employee bonuses due to lower-than-expected profits in 2024. The healthcare giant faced mounting costs, particularly from its Medicare plans, impacting overall financial performance.
A company spokesperson stated, “We did not meet our financial goals in 2024, and that’s reflected in our corporate bonus.”
CVS experienced a surge in Medicare enrollments, leading to increased expenses. The company also struggled with higher medical service utilization, a shift in quality ratings, and elevated costs from sicker Medicaid members. These factors contributed to financial setbacks, prompting executive changes and restructuring efforts.
In October, CVS replaced CEO Karen Lynch with longtime company executive David Joyner following investor pressure, including from activist Glenview Capital. Joyner has since initiated cost-cutting measures and appointed a new insurance head to stabilize operations.
Despite financial challenges, CVS recently exceeded Wall Street’s fourth-quarter profit expectations and provided an annual forecast aligning with analyst estimates. This signals potential improvement under the new leadership.
As CVS navigates economic headwinds, its strategic adjustments will be crucial in restoring growth and shareholder confidence.
